New

LPS B. quintana

This LPS molecule is derived from the cell membrane of the gram-negative bacterium Bartonella quintana. In contrast to LPS derived from Escherichia coli, B. quintana LPS is a potent antagonist of TLR4, as it inhibited both mRNA transcription and the release of tumor necrosis factor alpha, interleukin 1 (IL1), and IL-6.
Catalog #: HC4084-02
Quantity: 50 µg
$812.00

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

Description
Details
Humans as well as other vertebrates are often exposed to lipopolysaccharide (LPS), for instance via enterobacteria. LPS responses are mediated via Toll-like receptor 4 (TLR4), a member of the TLR protein family that play a fundamental role in pathogen recognition and activation of the innate immune system. TLR4 signaling activates various transcription factors like nuclear factor kappa-light-chain-enhancer (NF-κB), activator protein 1 (AP1), signal transducers and activators of transcription family of transcription factors (STAT1) and interferon regulatory factors (IRF's). This leads to the induction of several inflammatory pathways thereby promoting inflammation. Given the key role of the TLR4 signaling pathway in the induction of inflammation, it has been proposed that inhibition of this pathway has potential as a treatment for inflammatory disorders. This LPS molecule is derived from the cell membrane of the gram-negative bacterium Bartonella quintana. In contrast to LPS derived from Escherichia coli, B. quintana LPS is a potent antagonist of TLR4, as it inhibited both mRNA transcription and the release of tumor necrosis factor alpha, interleukin 1 (IL1), and IL-6. Because TLR4 proinflammatory signals are involved in a variety of pathological inflammatory reactions, the use of the TLR4 antagonistic properties of B. quintana LPS may be of potential therapeutic value.
Specifications

Specifications

Catalog number HC4084-02
Product type LPS and ligands
Quantity 50 µg
Source Bartonella quintana CIP 103739 Oklahoma strain
Formulation 50 µg LPS B. quintana in a concentration of 100 µg/ml in PBS
Storage and stability Product should be stored at -80°C. Store stock solution in aliquots at –80°C. Repeated freeze and thaw cycles will cause loss of activity. Under recommended storage conditions, product is stable for at least one year.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Disease Infectious diseases
Application
Applications
  • Application:
    FS
  • Use:
    FS: HC4084 is a potent TLR4 antagonist.
References
References
References:
1. Popa, C et al; Bartonella quintana Lipopolysaccharide Is a Natural Antagonist of Toll-Like Receptor 4. Infec and Immun 2007, 4831
2. Malgorzata-Miller, G et al; Bartonella quintana lipopolysaccharide (LPS): structure and characteristics of a potent TLR4 antagonist for in-vitro and in-vivo applications. Nature Scientific reports 2016, 6:34221
Downloads